SR 144528
CAS: 192703-06-3
Ref. 3D-BS179309
| 1mg | A consultar | ||
| 2mg | A consultar | ||
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar |
Información del producto
- 1H-Pyrazole-3-carboxamide, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-(1,3,3-trimethylbicyclo[2.2.1]hept-2-yl)-, (1S-endo)-
- 1H-pyrazole-3-carboxamide, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-
- 5-(4-Chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide
- Sr 144528
SR 144528 is a cannabinoid receptor antagonist. SR 144528 binds to the cytosolic C a 2 + channel and inhibits the release of Ca 2 + from intracellular stores. This effect results in decreased activation of MMP-9 and reduced production of proinflammatory cytokines. SR 144528 also suppresses mitochondrial membrane potential, leading to cell death by apoptosis. SR 144528 has been shown to have synergistic effects with low doses of glycol ethers, which may be due to its ability to inhibit energy metabolism and receptor activity.
Propiedades químicas
Consulta técnica sobre: 3D-BS179309 SR 144528
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
